Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Karuna Therapeutics stock

Own Karuna Therapeutics stock in just a few minutes.

Karuna Therapeutics, Inc is a biotechnology business based in the US. Karuna Therapeutics shares (KRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Karuna Therapeutics employs 63 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Karuna Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KRTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Karuna Therapeutics share price

Use our graph to track the performance of KRTX stocks over time.

Karuna Therapeutics shares at a glance

Information last updated 2021-04-29.
52-week range$69.58 - $146.97
50-day moving average $115.58
200-day moving average $105.50
Wall St. target price$161.62
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-254.14

Buy Karuna Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Karuna Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Karuna Therapeutics financials

Gross profit TTM $0
Return on assets TTM -11.78%
Return on equity TTM -18.81%
Profit margin 0%
Book value $6.94
Market capitalisation $3.3 billion

TTM: trailing 12 months

Shorting Karuna Therapeutics shares

There are currently 1.7 million Karuna Therapeutics shares held short by investors – that's known as Karuna Therapeutics's "short interest". This figure is 3.8% down from 1.8 million last month.

There are a few different ways that this level of interest in shorting Karuna Therapeutics shares can be evaluated.

Karuna Therapeutics's "short interest ratio" (SIR)

Karuna Therapeutics's "short interest ratio" (SIR) is the quantity of Karuna Therapeutics shares currently shorted divided by the average quantity of Karuna Therapeutics shares traded daily (recently around 182056.09492988). Karuna Therapeutics's SIR currently stands at 9.27. In other words for every 100,000 Karuna Therapeutics shares traded daily on the market, roughly 9270 shares are currently held short.

However Karuna Therapeutics's short interest can also be evaluated against the total number of Karuna Therapeutics shares, or, against the total number of tradable Karuna Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Karuna Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Karuna Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1143% of the tradable shares (for every 100,000 tradable Karuna Therapeutics shares, roughly 114 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Karuna Therapeutics.

Find out more about how you can short Karuna Therapeutics stock.

Karuna Therapeutics share dividends

We're not expecting Karuna Therapeutics to pay a dividend over the next 12 months.

Karuna Therapeutics overview

Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Karuna Therapeutics is owned by insiders or institutions?
Currently 9.875% of Karuna Therapeutics shares are held by insiders and 83.827% by institutions.
How many people work for Karuna Therapeutics?
Latest data suggests 63 work at Karuna Therapeutics.
When does the fiscal year end for Karuna Therapeutics?
Karuna Therapeutics's fiscal year ends in December.
Where is Karuna Therapeutics based?
Karuna Therapeutics's address is: 33 Arch Street, Boston, MA, United States, 02110
What is Karuna Therapeutics's ISIN number?
Karuna Therapeutics's international securities identification number is: US48576A1007
What is Karuna Therapeutics's CUSIP number?
Karuna Therapeutics's Committee on Uniform Securities Identification Procedures number is: 48576A100

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site